Khiron Life Sciences Corp. (KHRNF)
- CNW Group
Khiron Welcomes Dr. Eduardo Faveret as Medical Director for Brazil
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN)(OTCQX:KHRNF)(Frankfurt:A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the addition of renowned physician, pediatric neurologist and clinical physiologist, Dr. Eduardo Faveret, as Medical Director for Zerenia™ Brazil. As the Company expands its global leadership position, the addition of Dr. Faveret represents a major milestone toward bringing Khiro
- CNW Group
Colombia Expands Distribution of Medical Cannabis to Pharmacies Nationwide and Opens Export Market for Dried Flower Medical Cannabis
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announces its support for amendments to Colombia's medical cannabis decree, signed July 23, 2021. With the enhanced regulations, Colombia continues to be a leader and reference point for medical cannabis regulations across Latin America.
- CNW Group
Khiron Life Sciences Closes $12.3 Million Equity Financing
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has closed its offering to U.S. institutional investors of 27,435,000 units of the Company (the "Offered Units"), at a price of $0.45 per Offered Unit, for aggregate gross proceeds to the Company of $12,345,750, as previously announced on July 5, 2021 and July 6, 2021 (the "Offering").
